Enlivex randomizes 135 patients in Phase 2b Allocetra trial for knee osteoarthritis
ENLV•Enlivex has randomized 135 of 182 planned patients in its placebo-controlled Phase 2b Allocetra trial for knee osteoarthritis, and all have received their first injection. Six-month topline results are expected by mid-2027.
1. Trial enrollment continues
The study targets adults aged 64 and older with moderate-to-severe, age-related primary knee osteoarthritis. Enrollment is active in the United States, Denmark and Poland. Enlivex said previously reported Phase 1/2a results showed positive outcomes at three and six months, supporting FDA Regenerative Medicine Advanced Therapy designation in July 2026.
